Table 3.

Summary of immune effector cell toxicities.

	Number of subjects (%)
Cytokine release syndrome
Grade 1	7 (35%)
Grade 2	3 (15%)
Time from infusion to CRS onset, days, median (range)	4 (3-7)
Neurotoxicity
Grade 1 – 2	4 (20%)
Grade 3 – 4	1 (5%)
Time to neurotoxicity onset, days, median (range)	7 (5-9)
Intensive Care Unit transfer	1 (5%)
Mechanical ventilation	0
Post infusion tocilizumab, n (%)	5 (25%)
Post infusion corticosteroid, n (%)	4 (20%)
Post infusion anakinra, n (%)	2 (10%)
CRS: cytokine release syndrome